Deuterated derivatives of psilocybin and uses thereof
Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.
1. A pharmaceutical composition comprising a compound of Formula (IA-2):
or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof;
wherein the pharmaceutical composition comprises about 0.5 mg to 500 mg of the compound of Formula (IA-2).
2. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
3. The composition of claim 2 , wherein the composition is suitable for oral administration.
4. The composition of claim 2 , wherein the composition is suitable for intravenous (IV) administration.
5. The composition of claim 3 , wherein the composition is a solid dose composition.
6. The composition of claim 5 , wherein the solid dose composition is a tablet, capsule, granule, powder, sachet, or chewable.
7. The composition of claim 1 , wherein the composition comprises about 10 mg to about 250 mg of the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.
8. The composition of claim 1 , wherein the composition comprises about 0.5 mg to about 250 mg of the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.
9. The composition of claim 8 , wherein the composition comprises about 0.5 mg to about 50 mg of the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.
10. The composition of claim 9 , wherein the composition comprises about 10 mg to about 50 mg of the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.
11. The composition of claim 2 , wherein the composition comprises about 0.01 mg/ml to about 50 mg/ml of the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.
12. The composition of claim 2 , wherein the composition comprises about 0.001 mg/ml to about 0.1 mg/ml of the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.
13. The composition of claim 1 , wherein the composition comprises the compound of Formula (IA-2), or a pharmaceutically acceptable salt or prodrug thereof.
14. The composition of claim 1 , wherein the composition comprises the compound of Formula (IA-2), or a pharmaceutically acceptable salt thereof.